Mar 11, 2008|
US economy, MNC pharma & more...
Fears of a US recession were founded on Friday when the Bureau of Labour Statistics reported that the economy lost 63,000 non-farm jobs in February. This figure is considerably worse than the January data, which reported a revised decline of 22,000 jobs and has set the alarm bells ringing across the world. While the unemployment rate in the US dropping to 4.8% from 4.9% at first appears to provide some semblance of a relief, the same has been attributed to a reduction in the labour force as some people have given up looking for jobs. The US economy is now being haunted by falling house prices, rising energy and food prices, a weaker dollar, job cuts and declining consumer spending. This has impacted the country's stockmarkets, which in turn have had a negative bearing on the other markets around the world as well.
The gloom afflicting the global stockmarkets as a result has spilled over to India too with the BSE-Sensex displaying weakness yesterday following a turbulent week when the benchmark index fell by 9%. Inflation rising to 5% has not helped matters either and has possibly dimmed the chances of the RBI undertaking interest rate cuts. As against this, the expectations of the Fed cutting rates appear all the more imminent.
The healthcare index was the top performer last week registering losses of only 3% as against the Bankex, which registered a steep decline of 16%. While the uncertainty surrounding the waiver of the Rs 600 bn loan to small farmers was one reason why the banking sector was at the receiving end, the other was the revelation of ICICI Bank's exposure to the subprime crisis raising concerns that Indian banks were not completely insulated from the subprime malaise after all. As far as the waiver is concerned, the government is expected to compensate the banks either in bonds or cash over a period of three years. However, pressure on net interest margins (NIMs) is likely to persist till such time the banks are compensated. The pharma sector being a defensive play was not as affected as some of the other sectoral indices last week. One of the major reasons for the same can be attributed to the fact that notwithstanding a slowing growth in the economy, demand for medicines will prevail in the event of sickness, consequently supporting sales.
MNC pharma companies have had a dismal CY07, with the top four companies namely GSK Pharma, Pfizer, Aventis and Novartis reporting either decline in sales or growth in lower single digits. This has been due to various reasons namely supply shortages, lack of visible product launches and price control imposed by the DPCO. Having said that, two of these companies namely GSK Pharma and Pfizer have unveiled plans of launching new products into the country, which is an encouraging sign. Among the patented products, GSK Pharma has chalked out plans of launching 'Tykerb', an anti-cancer drug along with its vaccines 'Cervarix' and 'Rotarix'.
Pfizer, meanwhile, envisages the launch of its smoking cessation drug 'Champix' in India in the current year. This product was already launched in the global markets in CY06 and amassed revenues of US$ 883 m in CY07 (US$ 101 m in CY06). Similarly, GSK Pharma has already launched 'Tykerb' in the global markets (including the US) in CY07 and the drug has reported revenues of US$ 103 m in that year. Besides this, both the companies have announced plans to launch around two more products each, which will either be from the parent's product folio or through the in-licensing route. That said, these will not be eligible for patents in India and will have to contend with generic players, who have already launched their versions of the drugs. As we have mentioned earlier, while the initiatives taken by the companies to launch patented products in the country can indeed be construed as a positive sign, it remains to be seen as to how these products will be priced in a low priced market like India.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 22, 2017
It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407